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Gorlin syndrome or nevoid basal cell carcinoma syn-
drome is an autosomal dominant disease characterized
by developmental abnormalities and a predisposition to
cancers. The responsible gene for this syndrome is the
PTCH tumor suppressor gene encoding for the Sonic
Hedgehog receptor. We screened for PTCH mutations
in 65 French Gorlin syndrome families or sporadic cases
for the ¢rst time. Nineteen novel mutations and ¢ve
new polymorphisms were identi¢ed in this group of
patients. One microdeletion without frameshift
underlines the importance of one amino acid for Ptc
receptor function. Although no mutation hot-spot was des-
cribed, we identi¢ed a recurrent mutation. Key words:
basal cell/carcinoma/genetic/germline mutation/skin disease.
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G
orlin syndrome (Gorlin and Goltz, 1960) or nevoid
basal cell carcinoma syndrome (NBCCS) (Mende-
lian Inheritance in Man, MIM no. 109400) is an
autosomal dominant genetic disease with nearly
complete penetrance and variable expressivity.
NBCCS is characterized by development abnormalities and tu-
mor predisposition. The diagnosis is based on the occurrence of
three major criteria: basal cell carcinomas, palmar and plantar epi-
dermal pits, jaw keratocysts. Patients might display other clinical
features (Lo Muzio et al, 1999, and references therein).The severity
is due to the basal cell carcinomas and various di¡erent tumors
(Lacombe et al, 1990; Evans et al, 1993).
The NBCCS gene was localized to 9q22^31 by genetic linkage
studies (Farndon et al, 1992; Gailani et al, 1992). NBCCS tumors
show loss of heterozygosity in this region, arguing for a tumor
suppressor gene (Gailani et al, 1992; Levanat et al, 2000). The re-
sponsible gene PTCH has been identi¢ed by positional cloning
as the human homolog of the Drosophila patched gene (Hahn et al,
1996; Johnson et al, 1996). PTCH has 23 exons, which span 34 kb.
It encodes a transmembrane glycoprotein composed of 1447 ami-
no acids, with 12 transmembrane domains.
In 1996, two groups initially described germline mutations of
PTCH gene in Gorlin patients (Hahn et al, 1996; Johnson et al,
1996). Since these two reports, many PTCH germline mutations
have been described; most were frameshift or nonsense mutations
leading to the synthesis of a truncated Ptc protein (Chidambaram
et al, 1996; Unden et al, 1996; Lench et al, 1997;Wicking et al, 1997;
Aszterbaum et al, 1998; Hasenpusch-Theil et al, 1998; Smyth et al,
1998).
In this study, we have assessed the spectrum of PTCH germ-
line mutation in the French population.
MATERIALS ANDMETHODS
Patients Patients were evaluated by a geneticist for the presence of at
least one of the three main features of NBCCS. Sixty-¢ve families were
collected, 23 familial cases and 42 sporadic cases. Familial cases included
46 patients and 33 nona¡ected siblings. Nona¡ected unrelated individuals
from the same area were used to de¢ne a control population. The local
ethics committee approved this study, and patient informed consent was
obtained.
Mutation screening DNA was extracted with QIAmp Blood kit
(Qiagen Courtaboeuf, France). We used 24 pairs of primers previously
reported for the ampli¢cation of the 23 exons of the PTCH gene
(sequence no. U59464; exons 1^8, 11, 14^20, 23, and intron 1 (Hahn et al,
1996); exons 9 and 10 (Wolter et al, 1997); exons 12, 13, and 21 (Pietsch et al,
1997), and exon 22 (Chidambaram et al, 1996)) (detailed PCR procedures
are available upon request).
Single-strand conformation polymorphism or Heteroduplex Analysis
(HA) analyses were performed as described previously (Orita et al, 1989;
White et al, 1992). HA was conducted at 100 V, for 14 h. Single-strand
conformation polymorphism was realized on a Genephore electrophoresis
apparatus with GeneGel Clean 15/24 at 41C, 201C, 600 V, during 1 h
20 min. Staining was done with a silver staining kit (Pharmacia).
Sequencing of amplicons demonstrating band shifts was performed with
a Big Dye Terminator Cycle Sequencing kit on an ABI Prism 377
analyzer (Perkin-Elmer). Ampli¢cation product was sequenced on both
strands. Sequence analysis was conducted with a GCG sequence analysis
software package (University of Wisconsin).
RESULTS
We have screened the PTCH gene for mutations by PCR single-
strand conformation polymorphism or HA analysis in 65 family
or sporadic cases and identi¢ed 19 new mutations (Table I). Mu-
tation segregation with the disease in each family was tested.
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A total of 29 Gorlin patients bearing a PTCH mutation were
identi¢ed.
Nonsense and frameshift mutations Two nonsense mutations
were identi¢ed: Y224X, localized after the ¢rst transmembrane
domain, and Y873X, after the ¢rst group of transmembrane
domains.
We observed seven frameshift mutations giving rise to various
truncated Ptc proteins. They are deleted of at least the last four
transmembrane domains (cytosine deletion at 3042 in exon 18)
or deleted of all transmembrane domains at the most (complex
mutation in exon 2).
A two-nucleotide microdeletion at 1208^1209 in exon 8 was
identi¢ed in three di¡erent cases of NBCCS (one sporadic and
two familial cases), coming from di¡erent parts of France
without any evidence of familial links. Research for a common
allele was done with microsatellite markers D9S196, D9S287,
D9S1786, D9S180, D9S1783, and D9S109. No common morbid
haplotype is shared between these three cases (data not shown).
Finally, we identi¢ed, in a typical sporadic case of Gorlin
syndrome, a deletion of two nucleotides in intron 5 with A to
G substitution that occurs at the exonintron junction and
changes the nature of the nucleotide after the consensus
sequence (GT). It has not been found in a population of 100
control individuals and may alter the synthesis of the normal
mRNA.
Inframe deletion In a sporadic case, a three-nucleotide
microdeletion was identi¢ed in exon 3 deleting a conserved
glutamine among vertebrate species (Fig 1). This glutamine is
localized at the beginning of the ¢rst extracellular loop of
the Ptc receptor. This microdeletion was not detected in a
population of 100 control individuals.
Missense mutations In this study, we report six missense
mutations (Table I) occurring in exons 10, 11, 14, 15, 17, and 21.
G484R and P504L occur in the tenth transmembrane domain.
S647R is in the intracellular loop between the two groups of
transmembrane domains. L822P and W926R are localized in an
extracellular loop. Finally, T1195S occurs at the C-terminal
intracellular end. These sequence variations have not been found
in a population of 200 control chromosomes.They segregate with
the disease in familial cases of NBCCS.
Polymorphisms DNA variants were classi¢ed as
polymorphisms either because they do not lead to amino acid
change, or because there is no segregation with the disease in the
family, or because they were found in a cohort of 200 normal
chromosomes (Table I). Eleven polymorphisms were identi¢ed,
of which ¢ve have not been described before (N929N, A1157A,
L1175W, IVS5þ12 A4G, and IVS7þ 74 A4G). They appear in
the general population at the following frequencies: T245T
(10%), intron 5 (2%), intron 7 (o1%), intron 10 (14.5%),
N555N (10%), A562A (13%), intron 15 (6%), N929N (o1%),
A11571 (2%), L1175W (2%), and L1315P (6%).
DISCUSSION
We screened French NBCCS patients and identi¢ed 19 novel mu-
tations with 11 polymorphisms (Table I). In agreement with the
literature, we found mainly frameshift mutations; most of them
are characterized by a truncated protein lacking the last group of
six transmembrane domains. The high prevalence of typical
Table I. Mutations and polymorphisms detected in the
PTCH 1 gene
Mutations Exon Nucleotide change E¡ect on protein
1 2 c260del5TinsAA L87del, stop at 87
2 2 280insA 94 frameshift, stop at 138
3 3 c531del ACA Q177del
4 5 c672C4A Y224X
5 5 c742delCTinsGGAG 248 frameshift, stop at 249
6 intron 5 IVS5þ3 del AA
7 8 c1194delCinsATATG 398 frameshift, stop at 436
8 8 c1208delAT 403 framshift, stop at 435
9 8 c1208delAT 403 frameshift, stop at 435
10 8 c1208delAT 403 frameshift, stop at 435
11 10 c1450G4A G484R
12 11 c1511C4T P504L
13 14 c1941C4A S647R
14 14 c2178insC 721 frameshift, stop at 736
15 15 c2465T4C L822P
16 16 c2619C4A Y873X
17 18 c3042delC 1014 frameshift, stop at 1048
18 17 c2776T4C W926R
19 21 c3583A4T T1195S
Polymorphisms
5 c735A4G T245T
intron 5 IVS5þ12A4G
intron 7 IVS7þ 74 A4G
intron 10 IVS10-52 G4C
12 c1665T4C N555N
12 c1686C4T A562A
intron 15 IVS15þ9 C4G
17 c2787C4T N929N
21 c3471G4A A1157A
21 c3524T4G L1175W
23 c3944T4C L1315P
Figure1. Identi¢cation of mutation Q177del in exon 3 of the PTCH
gene. (A) DNA sequencing of the ACA deletion. (B) Amino acid sequence
conservation of the mutated amino acid. Alignment of the amino acid se-
quences of human (Hs), mouse (Mm), zebra¢sh (Dr), chicken (Gg), and
Xenopus (Xl) PTCH protein (GenBank Accession nos. U59464, U46155,
AJ007742, U40074, and AF302765, respectively). The deleted amino acid is
boxed.
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sporadic cases in our study, however, underlines the high fre-
quency of PTCH spontaneous mutations (Aszterbaum et al, 1998;
Hasenpusch-Theil et al, 1998; Smyth et al, 1998; and references
therein).
PTCH mutations are irregularly distributed along the coding
sequence and no hot-spot mutations have been reported yet. The
frameshift mutation in exon 8 is found in three di¡erent families,
however (G, H, I inTable II). So far, no founder e¡ect of PTCH
gene mutations has been described in the literature.We did not
¢nd any arguments to support a founder e¡ect. Indeed, some
mutations in di¡erent exons have been reported twice in the lit-
erature without any knowledge of recurrence (Hahn et al, 1996;
Wicking et al, 1997).We propose that mutation c1208^1209delAT
is the ¢rst truly recurrent mutation identi¢ed in PTCH gene. Pa-
tients bearing this mutation have a di¡erent clinical outcome,
which pinpoints the possible involvement of modi¢er genes as
identi¢ed for instance in neuro¢bromatosis type 1 (Bahuau et al,
2001). The identi¢cation of this mutation in monozygotic twins
displaying di¡erent clinical features, however (family G, pro-
bands G2 and G3,Table II), supports also the role of the environ-
ment (Nelson et al, 2002).
Interestingly, we report a unique deletion of a single amino
acid conserved in vertebrate species localized at the beginning of
the ¢rst extracellular loop of the receptor (Fig 1). It would be
interesting to know if this amino acid is important for the inter-
action of Hedgehog with its Ptc receptor. Unfortunately, no mu-
tagenesis data or binding studies are available to document the
e¡ect of this mutation.
Finally, we describe several sequence variations not found in
the general population segregating with the disease in the family,
considered as missense mutations. According to the literature,
missense mutations do not occur as frequently as frameshift or
nonsense mutations (15% vs 85%). They are spread along the
PTCH gene (Aszterbaum et al, 1998; Smyth et al, 1998; and refer-
ences therein). In our study, missense mutations span the second
group of six transmembrane domains of the protein. Molecular
and cellular studies on Ptc mutant proteins in Drosophila would
argue for disruption of the normal topology and/or sorting of
the receptor (Strutt et al, 2001). Unfortunately, such data are not
available to interpret the pathologic value of the missense muta-
tions described in humans.
Improvement of the PTCH gene screening is necessary but the
nondetection of PTCH mutations in half of the typical familial
cases might also underline the nonexploration of other genetic
events. Many studies have shown splice mutations (Aszterbaum
et al, 1998; Smyth et al, 1998; and references therein). Small dele-
tions encompassing several exons might also take place as has al-
ready been demonstrated in other cancer-prone genetic diseases
(Dorschner et al, 2000).
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Table II. Clinical ¢ndings in French Gorlin patients
Dysmorphology Tumors
Mutation
Case identi¢er Familial/Sporadic Sexe Age Pits Cysts Other BCC Other identi¢er
A.1 Familial F 18 þ þ þ þ 1
A.2 Familial F 40 þ þ þ 1
B Sporadic F 38 þ þ 2
C Sporadic M 20 þ þ þ 3
D Sporadic M 38 þ þ 4
E Familial F 41 þ þ þ 5
F Sporadic M 16 þ þ þ þ 6
G Familial M 7 þ 7
G.1 Familial M 64 þ þ þ þ 8
G.2 Familial M 33 þ þ 8
G.3 Familial M 33 þ þ þ þ 8
H Sporadic F 13 þ þ þ 9
I.1 Familial F 15 þ þ þ þ 10
I.1 Familial F 18 þ þ þ 10
I.1 Familial F 39 þ 10
J Familial G 39 þ þ þ þ 11
K Familial F 33 þ þ þ 12
L Familial F 37 þ þ 13
M.1 Familial F 15 þ 14
M.2 Familial M 41 þ 14
N.1 Familial M 55 þ þ þ þ þ 15
N.2 Familial F þ þ þ þ 15
O Sporadic M 30 þ þ 16
P Sporadic M 33 þ þ þ 17
Q.1 Familial F 19 þ þ þ þ 18
Q.2 Familial F 9 þ þ 18
Q.3 Familial F 16 þ þ þ 18
Q.4 Familial F 36 þ þ þ 18
R Sporadic M 50 þ þ 19
BCC, Basal Cell Carcinoma; M, male; F, female; Pits, palmar and plantar pits; Cysts, keratocysts; Dysmorphology other, any other dysmorphic symptom;Tumors other,
any type of tumor.
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